Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
Direxion Daily Energy Bear 2X Shares
ERY
VanEck Semiconductor ETF
SMH
4
SPDR S&P Homebuilders ETF
XHB
5
iShares US Home Construction ETF
ITB
US Stock MarketDetailed Quotes
BriaCell Therapeutics (BCTX)
- 2.900
- +0.100+3.57%
Close Jun 18 16:00 ET
- 2.830
- -0.070-2.41%
Pre 06:48 ET
25.23MMarket Cap-0.69P/E (TTM)
2.950High2.800Low54.65KVolume2.820Open2.800Prev Close157.97KTurnover0.70%Turnover RatioLossP/E (Static)8.70MShares31.10052wk High1.05P/B22.79MFloat Cap2.60052wk Low--Dividend TTM7.86MShs Float1870.500Historical High--Div Yield TTM5.36%Range %2.600Historical Low2.890Avg Price1Lot Size
BCTX Stock Chart
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
BCTX Orderflow
Unit: --
BCTX Orderflow Trend
IntradayDayWeekMonth
No Data
BriaCell Therapeutics (BCTX) News
Express News | BriaCell Therapeutics Q3 EPS $(0.99) Up From $(16.40) YoY
BriaCell Therapeutics Corp: INTERIM MDA EN
BriaCell Therapeutics Corp: INTERIM FINANCIAL STATEMENTSREPORT EN
10-Q: Quarterly report
BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering
BriaCell Therapeutics Closes $4.7 Million Share Offering
BriaCell Therapeutics (BCTX) Stock Forum
$BriaCell Therapeutics (BCTX.US)$ BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
3 minutes ago, 7:30 AM EDT
Via GlobeNewswire
Bria-PROS+ is BriaCell's next generation personalized off-the-shelf immunotherapy for prostate cancer
Immune stimulating components of Bria-PROS+ enhance anti-tumor responses
BriaCell has completed manufacturing clinical supplies of Bria-PROS+ and plans to initiate a Phase 1/2a clinical study in prostate cancer in the coming mo...
3 minutes ago, 7:30 AM EDT
Via GlobeNewswire
Bria-PROS+ is BriaCell's next generation personalized off-the-shelf immunotherapy for prostate cancer
Immune stimulating components of Bria-PROS+ enhance anti-tumor responses
BriaCell has completed manufacturing clinical supplies of Bria-PROS+ and plans to initiate a Phase 1/2a clinical study in prostate cancer in the coming mo...
$BriaCell Therapeutics (BCTX.US)$ BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
1 minute ago, 7:30 AM EDT
Via GlobeNewswire
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancer
Bria-BRES+ is BriaCell's next generation personalized immunotherapy for breast cancer, and features additional immune activating components designed to enhance clinical efficacy
B...
1 minute ago, 7:30 AM EDT
Via GlobeNewswire
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancer
Bria-BRES+ is BriaCell's next generation personalized immunotherapy for breast cancer, and features additional immune activating components designed to enhance clinical efficacy
B...
2
$BriaCell Therapeutics (BCTX.US)$
Abstract Title: Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months.
Session Type/Title: Poster Session - Breast Cancer—Metastatic
Poster Board: 222
Date and Time: June 1, 2026, 1:30 PM-4:30 PM CDT
Abstract Title: Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months.
Session Type/Title: Poster Session - Breast Cancer—Metastatic
Poster Board: 222
Date and Time: June 1, 2026, 1:30 PM-4:30 PM CDT
1
$BriaCell Therapeutics (BCTX.US)$
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
26 seconds ago, 1:05 PM PDT
Via GlobeNewswire
BCTXBCTXLBCTXWBCTXZ
Share
PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL)) (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-...
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
26 seconds ago, 1:05 PM PDT
Via GlobeNewswire
BCTXBCTXLBCTXWBCTXZ
Share
PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL)) (TSX:BCT) ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-...
3
$BriaCell Therapeutics (BCTX.US)$ There are four important posters from BriaCell to be presented in AACR 2026 conference. Here is one of them.
Session PO.CL05.13 - Vaccines and Other Immunomodulatory Agents
6701 / 12 - Re-engineering cancer vaccines: Bria-OTS+ integrates innate and adaptive immunity for broad and persistent anti-tumor responses
1) Bria-OTS+ is a next-generation, genetically engineered whole-cell cancer vaccine platform designed to overcome the l...
Session PO.CL05.13 - Vaccines and Other Immunomodulatory Agents
6701 / 12 - Re-engineering cancer vaccines: Bria-OTS+ integrates innate and adaptive immunity for broad and persistent anti-tumor responses
1) Bria-OTS+ is a next-generation, genetically engineered whole-cell cancer vaccine platform designed to overcome the l...
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)